MedPath

Sapanisertib

Generic Name
Sapanisertib
Drug Type
Small Molecule
Chemical Formula
C15H15N7O
CAS Number
1224844-38-5
Unique Ingredient Identifier
JGH0DF1U03
Background

Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.

Clinical Trials
Related News

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Lung Non-Small Cell Carcinoma
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Recurrent Lung Non-Small Cell Carcinoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2015-07-21
Last Posted Date
2025-03-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
36
Registration Number
NCT02503722
Locations
πŸ‡ΊπŸ‡Έ

Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States

πŸ‡ΊπŸ‡Έ

Moffitt Cancer Center, Tampa, Florida, United States

πŸ‡¨πŸ‡¦

BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 2 locations

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Phase 2
Completed
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
B Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Recurrent Adult Acute Lymphoblastic Leukemia
T Acute Lymphoblastic Leukemia
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2015-06-29
Last Posted Date
2025-03-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
16
Registration Number
NCT02484430
Locations
πŸ‡ΊπŸ‡Έ

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

πŸ‡ΊπŸ‡Έ

City of Hope Comprehensive Cancer Center, Duarte, California, United States

πŸ‡ΊπŸ‡Έ

Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 11 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2
Active, not recruiting
Conditions
Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Bladder Carcinoma
Breast Carcinoma
Cervical Carcinoma
Colon Carcinoma
Colorectal Carcinoma
Endometrial Carcinoma
Esophageal Carcinoma
Exocrine Pancreas Carcinoma
Interventions
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Cytology Specimen Collection Procedure
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography Test
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Procedure: Radionuclide Imaging
First Posted Date
2015-06-08
Last Posted Date
2025-05-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
6452
Registration Number
NCT02465060
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Thomas Hospital, Fairhope, Alabama, United States

πŸ‡ΊπŸ‡Έ

Mobile Infirmary Medical Center, Mobile, Alabama, United States

and more 1406 locations

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

Phase 2
Completed
Conditions
Recurrent Lung Squamous Cell Carcinoma
Stage IV Lung Squamous Cell Carcinoma AJCC v7
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2015-04-16
Last Posted Date
2022-04-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
34
Registration Number
NCT02417701
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Commack, Commack, New York, United States

and more 4 locations

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

Phase 1
Completed
Conditions
Non-hematologic Malignancy
Interventions
First Posted Date
2015-04-09
Last Posted Date
2020-02-28
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
61
Registration Number
NCT02412722

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Phase 1
Completed
Conditions
Advanced Nonhematologic Malignancies
Interventions
First Posted Date
2014-12-30
Last Posted Date
2020-02-25
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
81
Registration Number
NCT02327169
Locations
πŸ‡ΊπŸ‡Έ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 11 locations

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Phase 1
Completed
Conditions
Anaplastic Thyroid Cancer
Thyroid Cancer
Differentiated Thyroid Cancer
Interventions
First Posted Date
2014-09-19
Last Posted Date
2024-01-12
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
46
Registration Number
NCT02244463
Locations
πŸ‡ΊπŸ‡Έ

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

πŸ‡ΊπŸ‡Έ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

University of Michigan Medical School, Ann Arbor, Michigan, United States

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2014-07-22
Last Posted Date
2023-01-23
Lead Sponsor
Calithera Biosciences, Inc
Target Recruit Count
44
Registration Number
NCT02197572

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1
Completed
Conditions
Metastatic Malignant Solid Neoplasm
Unresectable Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Fibrolamellar Carcinoma
Ovarian Carcinoma
Pancreatic Neuroendocrine Tumor
Advanced Malignant Solid Neoplasm
Interventions
Biological: Ziv-Aflibercept
First Posted Date
2014-06-10
Last Posted Date
2024-02-28
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
83
Registration Number
NCT02159989
Locations
πŸ‡ΊπŸ‡Έ

M D Anderson Cancer Center, Houston, Texas, United States

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Adult Glioblastoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Malignant Uterine Corpus Neoplasm
Recurrent Ovarian Carcinoma
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2014-05-20
Last Posted Date
2025-03-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT02142803
Locations
πŸ‡ΊπŸ‡Έ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Massachusetts General Hospital, Charlestown, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy